In this week’s episode, we’ll discuss a recent U.S. Food and Drug Administration (FDA) approval in the early-stage non–small cell lung cancer setting. Then, we’ll hear about a study presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium that investigated methods for the de-escalation of radiation therapy for oropharyngeal cancer.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Neoadjuvant Nivolumab and Platinum Doublet Chemotherapy for Early-Stage NSCLC

Midtreatment Imaging De-escalates Therapy for Half of Patients With Oropharyngeal Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.